AVADEL PHARMACEUTICALS PLC Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q1 2012 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Avadel Pharmaceuticals Plc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q1 2012 to Q2 2024.
- Avadel Pharmaceuticals Plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending June 30, 2024 was -$14.3M, a 77.8% increase year-over-year.
- Avadel Pharmaceuticals Plc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending June 30, 2024 was -$104M, a 26.6% increase year-over-year.
- Avadel Pharmaceuticals Plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$157M, a 12.3% decline from 2022.
- Avadel Pharmaceuticals Plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$140M, a 74.4% decline from 2021.
- Avadel Pharmaceuticals Plc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$80.2M, a 1013% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)